4//SEC Filing
Combs Andrew 4
Accession 0001209191-22-022524
CIK 0001678660other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 5:08 PM ET
Size
7.3 KB
Accession
0001209191-22-022524
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-01−36,062→ 50,397 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (36,062 underlying) - Exercise/Conversion
Common Stock
2022-03-31$1.89/sh+36,062$68,157→ 304,442 total
Footnotes (2)
- [F1]Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
- [F2]The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Documents
Issuer
Prelude Therapeutics Inc
CIK 0001678660
Entity typeother
Related Parties
1- filerCIK 0001825005
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 5:08 PM ET
- Size
- 7.3 KB